threonine has been researched along with Hematologic Malignancies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ábrányi-Balogh, P; Csányi, D; Ferenczy, GG; Gobec, M; Gobec, S; Gömöry, Á; Imre, T; Keserű, GM; Knez, D; Kollár, L; Petri, L; Proj, M; Smrdel, L; Sosič, I | 1 |
| Chantepie, S; Damaj, G; Decamp, M; Henry, A; Hueso, T; Johnson-Ansah, H; Maitre, E; Mensi, S; Vilque, JP | 1 |
2 other study(ies) available for threonine and Hematologic Malignancies
| Article | Year |
|---|---|
Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads.
Topics: Autoimmune Diseases; Benzoxazoles; Computational Chemistry; Cysteine; Hematologic Neoplasms; Humans; Inflammation; Models, Molecular; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Structure-Activity Relationship; Threonine; Ubiquitin | 2021 |
Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
Topics: Amino Acid Substitution; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Isoleucine; Male; Middle Aged; Mutation, Missense; Myeloproliferative Disorders; Neoadjuvant Therapy; Receptors, Colony-Stimulating Factor; Threonine; Transplantation, Homologous; Treatment Outcome | 2019 |